Skip to main content

2 Result(s)

within Philip Galebach Remove this filter Oncology Remove this filter

and

  1. No Access

    Article

    Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study

    This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received c...

    Edmond Bendaly, Anand A. Dalal, Kenneth Culver, Philip Galebach… in Advances in Therapy (2017)

  2. No Access

    Article

    Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients

    Crizotinib is recommended as first-line therapy for ALK-positive non-small cell lung cancer (NSCLC), but within a year of treatment initiation many patients develop resistance. With the recent approval of second-...

    Edmond Bendaly, Anand A. Dalal, Kenneth Culver, Philip Galebach… in Advances in Therapy (2017)